Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 20 Breast Neoplasms 11 Prostatic Neoplasms 10 Neoplasms 7 Neoplasm Metastasis 7 Fallopian Tube Neoplasms 7 Pancreatic Neoplasms 6 Endometrial Neoplasms 5 Triple Negative Breast Neoplasms 4 Lung Neoplasms 3 Head and Neck Neoplasms 3 Glioblastoma 3 Carcinoma, Ovarian Epithelial 3 Small Cell Lung Carcinoma 2 Prostatic Neoplasms, Castration-Resistant 2 Glioma 2 Carcinoma, Non-Small-Cell Lung 2 Brain Neoplasms 2 Biliary Tract Neoplasms 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urologic Neoplasms 1 Urinary Bladder Neoplasms 1 Unilateral Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma 1 SCLC,Extensive Stage 1 Recurrence 1 Rectal Neoplasms 1 Prostate Adenocarcinoma 1

Interventions

Cyclophosphamide 51 fludarabine 37 Dexamethasone 35 venetoclax 30 pembrolizumab 25 Rituximab 20 pomalidomide 18 Lenalidomide 17 Gemcitabine 17 fludarabine phosphate 15 Etoposide 14 Cytarabine 13 daratumumab 12 carfilzomib 11 Temozolomide 11 Injections 10 Calcium Dobesilate 10 glofitamab 9 Nivolumab 9 Cisplatin 9 Bortezomib 9 Azacitidine 9 selinexor 8 Vincristine 8 Immunotherapy, Adoptive 8 obinutuzumab 7 cemiplimab 7 Drug Therapy 7 Carboplatin 7 zanubrutinib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × niraparib × 1 year × Clear all

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡